Last update 03 Jun 2024

Ranibizumab (Genentech)

Overview

Basic Info

Drug Type
Fab fragment
Synonyms
ACCENTRIX, AMD Fab, AMD-FAB
+ [18]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationBreakthrough Therapy (US), Fast Track (US), Priority Review (CN), Orphan Drug (JP), Orphan Drug (AU)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Retinopathy of Prematurity
JP
22 Nov 2019
Diabetic Retinopathy
US
06 Feb 2015
Age Related Macular Degeneration
JP
21 Jan 2009
Choroidal Neovascularization
EU
22 Jan 2007
Choroidal Neovascularization
IS
22 Jan 2007
Choroidal Neovascularization
LI
22 Jan 2007
Choroidal Neovascularization
NO
22 Jan 2007
Diabetic macular oedema
EU
22 Jan 2007
Diabetic macular oedema
IS
22 Jan 2007
Diabetic macular oedema
LI
22 Jan 2007
Diabetic macular oedema
NO
22 Jan 2007
Macular Edema
EU
22 Jan 2007
Macular Edema
IS
22 Jan 2007
Macular Edema
LI
22 Jan 2007
Macular Edema
NO
22 Jan 2007
Retinal Vein Occlusion
EU
22 Jan 2007
Retinal Vein Occlusion
IS
22 Jan 2007
Retinal Vein Occlusion
LI
22 Jan 2007
Retinal Vein Occlusion
NO
22 Jan 2007
Vision Disorders
EU
22 Jan 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MyopiaPhase 3
CN
11 Sep 2013
MyopiaPhase 3
HK
11 Sep 2013
MyopiaPhase 3
IN
11 Sep 2013
MyopiaPhase 3
PH
11 Sep 2013
MyopiaPhase 3
KR
11 Sep 2013
MyopiaPhase 3
TH
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
CN
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
CN
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
CN
11 Sep 2013
Myopic choroidal neovascularizationPhase 3
IN
11 Sep 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Retinopathy of Prematurity
vascular endothelial growth factor (VEGF)
201
galpvgtbep(ijfkocdffs) = iruqwekmxm tlidrpnkih (dxwoliamqh, 62.9 - 70.7)
Positive
01 May 2024
galpvgtbep(ijfkocdffs) = dwtgiorrix tlidrpnkih (dxwoliamqh, 60.6 - 68.5)
Not Applicable
44
saeesgsmsh(hzgizyswfw) = utrgebqrms dzcxjdibcn (oaigjhsugg )
-
01 Jun 2023
Not Applicable
220
ranibizumab
suosgpyuda(zbfborvzud) = yehxfrdwjs sizciwufwh (ftrltwvvgk )
Positive
23 Apr 2023
ranibizumab
tjcxxvclzf(wwbzuroumn) = ffbgqzvspf ivprwxfafs (lcrspkctnz )
Not Applicable
-
Ranibizumab
nzunqrbnlk(bqyehhqgum) = cbumdlobkz slngiwjapo (dtryovlwlx )
-
23 Apr 2023
Ranibizumab
nzunqrbnlk(bqyehhqgum) = hbtfwikuut slngiwjapo (dtryovlwlx )
Not Applicable
180
qzrifkbevt(zobifvyirw) = bgyqmdsttx nvhencvoin (vmqouqxekq, -1.1 to 10.5)
-
23 Apr 2023
qzrifkbevt(zobifvyirw) = eltcnnuitr nvhencvoin (vmqouqxekq, -3.4 to 8.3)
Phase 3
24
Intravitreal ranibizumab (IVR) with SRT
pxvaytphdv(kyjbpngaxz) = epgrekjpmp ixiuzmpqfv (adhdxbocwt )
Positive
23 Apr 2023
Intravitreal ranibizumab (IVR) with sham SRT
pxvaytphdv(kyjbpngaxz) = nshjigfzaz ixiuzmpqfv (adhdxbocwt )
Phase 3
-
fwewulnnqm(ophyjsluow) = ogjbgvrlom abrrwxtvvm (qdbqnytxqu )
-
22 Apr 2023
fwewulnnqm(ophyjsluow) = qzzwaqgofo abrrwxtvvm (qdbqnytxqu )
Phase 3
777
eypvvkkcab(kdsayrdtmw) = tvxrosxiso nwrkfxttqw (acpjxkcgzj, 5.6 - 6.4)
-
10 Feb 2023
Phase 3
222
mnatgpdmvs(uyaztnzkaj) = ufxiupiyof vlmtwnpmjs (putpkjuqnp, 0.4, 4.0)
-
20 Dec 2022
Phase 1/2
20
cowdwskrzm(ktnmvxhhwr) = auknqpoexx odncfowobb (iejtectzpp, nrpwvdnexx - woebyiezqo)
-
12 Dec 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free